Терапевтический архив, 2009 Aim. To analyse the data on infliximab administration (efficacy, tolerance, toxicity) in patients with rheumatoid arthritis (RA) in Russia by clinical evidence provided by the multicenter observation trial. Material and methods. The register included 297
Galina Viktorovna Lukina +5 more
doaj
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study [PDF]
, 2011 Denis Mulleman +6 more
openalex +1 more source
Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study
JEADV Clinical Practice, EarlyView.ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis highly associated with systemic comorbidities. Accurate diagnosis and treatment remain challenging due to its rarity and clinical mimickers. Objectives To evaluate demographic, clinical features and treatment outcomes in patients referred with suspected PG at a tertiary ...
David Croitoru +13 more
wiley +1 more source
Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update
Clinical and Experimental Gastroenterology, 2009 Garrett Lawlor, Alan C MossBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USAAbstract: Infliximab is a monoclonal antibody against tumor necrosis factor (TNF) which has become an established therapy for Crohn’s ...
Garrett Lawlor, Alan C Moss
doaj
A Low Neutrophil CD64 Index Is Associated with Sustained Remission During Infliximab Maintenance Therapy [PDF]
, 2016 Phillip Minar +7 more
openalex +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin +4 more
wiley +1 more source
Treatment of pyoderma gangrenosum (PG) complicating Crohn's disease (CD) with infliximab
, 2001 John J. Hong +2 more
openalex +1 more source
Efficacy of certolizumab pegol in Crohnʼs disease patients with secondary failure to infliximab is not affected by concommittant medications [PDF]
, 2009 William J. Sandborn +11 more
openalex +1 more source
New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa
JEADV Clinical Practice, EarlyView.ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender +2 more
wiley +1 more source
Hepatobiliary and Pancreatic: Pyoderma gangrenosum of the pancreas successfully treated with infliximab [PDF]
, 2018 Nele Deprez +3 more
openalex +1 more source